| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Department of Clinical and Molecular Endocrinology and Oncology, University Federico II (A.C., P.M., D.F., G.C., V.M., A.D.S., B.M., G.L.), and Emergency Unit, Ospedale Incurabili (S.S.), 80131 Naples, Italy
Address all correspondence and requests for reprints to: Annamaria Colao, M.D., Ph.D., Department of Clinical and Molecular Endocrinology and Oncology, University Federico II, Via S. Pansini 5, 80131 Naples, Italy.
This study was designed to investigate whether GH and insulin-like growth factor I (IGF-I) excess could lead to the development of benign prostatic hyperplasia and/or prostatic carcinoma. Prostatic diameters and volume as well as the occurrence of prostatic diseases were studied by ultrasonography in 10 untreated acromegalic patients less than 40 yr of age and 10 age- and body mass index-matched healthy males. Serum GH, IGF-I, PRL, testosterone, dihydrotestosterone, prostate-specific antigen, and prostatic acid phosphatase levels were assessed. All patients had secondary hypogonadism, as diagnosed by low testosterone levels, and 4 of 10 patients had hyperprolactinemia. After 1 yr of treatment with octreotide (0.3–0.6 mg/day), ultrasound scan and hormone parameters were repeated. The 4 hyperprolactinemic acromegalics were treated with octreotide and cabergoline (1–2 mg/week) to suppress PRL levels.
Symptoms due to prostatic, seminal vesicle, and/or urethral disorders
or obstruction were experienced by neither acromegalics nor controls.
Digital rectal examination revealed no occurrence of prostatic nodules
or other abnormalities. Compared to healthy subjects, a remarkable
increase in transversal prostatic diameter and volume was observed in
acromegalics. In healthy subjects, prostate volume ranged from
15.1–21.8 mL, whereas in acromegalics it ranged from 21.8–41.8 mL.
Similarly, an increased median lobe was observed. In fact, the
transitional zone diameter was just detectable in 5 of 10 controls,
whereas it was measurable in all acromegalics (18 ± 1.2
vs. 2.8 ± 0.3 mm; P < 0.001).
The prevalence of periurethral calcifications was more than doubled in
acromegalics (50%) compared to that in controls (20%). Treatment with
octreotide for 1 yr produced normalization of circulating GH and IGF-I
levels in 7 of 10 patients. In these 7 patients, ultrasound evaluation
showed a significant reduction of the antero-posterior diameter
(26.1 ± 1 vs. 28.9 ± 1.6 mm;
P < 0.01), the transversal diameter (44.9 ±
2 vs. 48 ± 2 mm; P < 0.01),
and the cranio-caudal diameter (36.5 ± 1 vs.
41.3 ± 1.5 mm; P < 0.001), whereas the
transitional zone diameter was unchanged (16.4 ± 1.5
vs. 17.4 ± 1.7 mm). As a consequence, a
significant decrease in prostate volume was recorded (22.1 ± 1.1
vs. 29.8 ± 2.5 mL; P <
0.001). Prostate volume increased in 2 of the 3 patients who did not
achieve normalization of GH and IGF-I after octreotide treatment.
Finally, after treatment, serum testosterone levels were significantly
increased (from 1.5 ± 0.3 to 3.5 ± 0.3 µg/L), whereas
dihydrotestosterone, dehydroepiandrosterone sulfate,
4-androstenedione, 17ß-estradiol, prostate-specific
antigen, and prostatic acid phosphatase were unchanged. Serum PRL
levels were suppressed after cabergoline treatment in all 4
hyperprolactinemic patients throughout the study period.
In conclusion, prostate enlargement occurs in young acromegalics with a higher than expected prevalence of micro- and macrocalcifications. This suggests that a careful prostate screening should be included in the work-up and follow-up of acromegalic males.
This article has been cited by other articles:
 |
|
 |
|
  J. Svensson, J. Kindblom, R. Shao, S. Moverare-Skrtic, M. K Lagerquist, N. Andersson, K. Sjogren, K. Venken, D. Vanderschueren, J.-O. Jansson, et al. Liver-derived IGF1 enhances the androgenic response in prostate J. Endocrinol., December 1, 2008; 199(3): 489 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Wang, R. M. Luque, R. D. Kineman, V. H. Ray, K. T. Christov, D. D. Lantvit, T. Shirai, S. Hedayat, T. G. Unterman, M. C. Bosland, et al. Disruption of Growth Hormone Signaling Retards Prostate Carcinogenesis in the Probasin/TAg Rat Endocrinology, March 1, 2008; 149(3): 1366 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. LeBaron, T. J. Ahonen, M. T. Nevalainen, and H. Rui In Vivo Response-Based Identification of Direct Hormone Target Cell Populations Using High-Density Tissue Arrays Endocrinology, March 1, 2007; 148(3): 989 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Kleinberg, W. Ruan, D. Yee, K. T. Kovacs, and S. Vidal Insulin-Like Growth Factor (IGF)-I Controls Prostate Fibromuscular Development: IGF-I Inhibition Prevents Both Fibromuscular and Glandular Development in Eugonadal Mice Endocrinology, March 1, 2007; 148(3): 1080 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Harman and M. R. Blackman Hormones and Supplements: Do They Work?: Use of Growth Hormone for Prevention or Treatment of Effects of Aging J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2004; 59(7): B652 - B658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Colao, G. Vitale, A. Di Sarno, S. Spiezia, E. Guerra, A. Ciccarelli, and G. Lombardi Prolactin and Prostate Hypertrophy: A Pilot Observational, Prospective, Case-Control Study in Men with Prolactinoma J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2770 - 2775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Colao, D. Ferone, P. Marzullo, and G. Lombardi Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management Endocr. Rev., February 1, 2004; 25(1): 102 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. O. Roberts, D. J. Jacobson, C. J. Girman, T. Rhodes, G. G. Klee, M. M. Lieber, and S. J. Jacobsen Insulin-like Growth Factor I, Insulin-like Growth Factor Binding Protein 3, and Urologic Measures of Benign Prostatic Hyperplasia Am. J. Epidemiol., May 1, 2003; 157(9): 784 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Colao, C. Di Somma, S. Spiezia, M. Filippella, R. Pivonello, and G. Lombardi Effect of Growth Hormone (GH) and/or Testosterone Replacement on the Prostate in GH-Deficient Adult Patients J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 88 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Colao, M. De Rosa, R. Pivonello, A. Balestrieri, P. Cappabianca, A. Di Sarno, V. Rochira, C. Carani, and G. Lombardi Short-Term Suppression of GH and IGF-I Levels Improves Gonadal Function and Sperm Parameters in Men with Acromegaly J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4193 - 4197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Jenkins and M. Besser CLINICAL PERSPECTIVE: Acromegaly and Cancer: A Problem J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2935 - 2941. [Full Text] [PDF]
|
|
|
|
|
|
P. Stattin, S. Söderberg, G. Hallmans, A. Bylund, R. Kaaks, U.-H. Stenman, A. Bergh, and T. Olsson Leptin Is Associated with Increased Prostate Cancer Risk: A Nested Case-Referent Study J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1341 - 1345. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. UNTERGASSER, H. RUMPOLD, E. PLAS, S. MADERSBACHER, and P. BERGER A low-molecular-weight fraction of human seminal plasma activates adenylyl cyclase and induces caspase 3-independent apoptosis in prostatic epithelial cells by decreasing mitochondrial potential and Bcl-2/Bax ratio FASEB J, March 1, 2001; 15(3): 673 - 683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Colao, P. Marzullo, S. Spiezia, A. Giaccio, D. Ferone, G. Cerbone, A. Di Sarno, and G. Lombardi Effect of Two Years of Growth Hormone and Insulin-Like Growth Factor-I Suppression on Prostate Diseases in Acromegalic Patients J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3754 - 3761. [Abstract] [Full Text]
|
|
|
|
|
|
A. G. Renehan, P. Bhaskar, J. E. Painter, S. T. O’Dwyer, N. Haboubi, J. Varma, S. G. Ball, and S. M. Shalet The Prevalence and Characteristics of Colorectal Neoplasia in Acromegaly J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3417 - 3424. [Abstract] [Full Text]
|
|
|
|
|
|
P. Finne, A. Auvinen, H. Koistinen, W.-M. Zhang, L. Määttänen, S. Rannikko, T. Tammela, M. Seppälä, M. Hakama, and U.-H. Stenman Insulin-Like Growth Factor I Is Not a Useful Marker of Prostate Cancer in Men with Elevated Levels of Prostate-Specific Antigen J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2744 - 2747. [Abstract] [Full Text]
|
|
|
|
|
|
T. J. Ahonen, P. L. Härkönen, J. Laine, H. Rui, P. M. Martikainen, and M. T. Nevalainen Prolactin Is a Survival Factor for Androgen-Deprived Rat Dorsal and Lateral Prostate Epithelium in Organ Culture Endocrinology, November 1, 1999; 140(11): 5412 - 5421. [Abstract] [Full Text]
|
|
|
|
|
|
A. Colao, P. Marzullo, S. Spiezia, D. Ferone, A. Giaccio, G. Cerbone, R. Pivonello, C. Di Somma, and G. Lombardi Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1986 - 1991. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. J. Kaplan, S. Mohan, P. Cohen, B. A. Foster, and N. M. Greenberg The Insulin-like Growth Factor Axis and Prostate Cancer: Lessons from the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Model Cancer Res., May 1, 1999; 59(9): 2203 - 2209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Hwa, C. Tomasini-Sprenger, A. López Bermejo, R. G. Rosenfeld, and S. R. Plymate Characterization of Insulin-Like Growth Factor-Binding Protein-Related Protein-1 in Prostate Cells J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4355 - 4362. [Abstract] [Full Text]
|
|
|
|
|
|
A. Colao, P. Marzullo, and G. Lombardi Prostatic Hyperplasia in Patients with Acromegaly--Authors' Response J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2606a - 2607. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
